Hofseth BioCare (HOFB.F) Stock Overview
Produces and sells health nutritional products for humans and pets in Norway, the United Kingdom, France, Belgium, Italy, Germany, rest of Europe, Japan, Asia, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
HOFB.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Hofseth BioCare ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 0.17 |
| 52 Week High | NOK 0.17 |
| 52 Week Low | NOK 0.095 |
| Beta | 0.53 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | -81.28% |
| Change since IPO | -51.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| HOFB.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.7% | 4.2% |
| 1Y | n/a | 37.1% | 29.0% |
Return vs Industry: Insufficient data to determine how HOFB.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how HOFB.F performed against the US Market.
Price Volatility
| HOFB.F volatility | |
|---|---|
| HOFB.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: HOFB.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine HOFB.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 75 | Jon Odegard | www.hofsethbiocare.com |
Hofseth BioCare ASA produces and sells health nutritional products for humans and pets in Norway, the United Kingdom, France, Belgium, Italy, Germany, rest of Europe, Japan, Asia, and the United States. The company offers ProGo, a bioactive peptide for weight management and metabolic health; OmeGo, a salmon oil that provides a full spectrum of fatty acids and omegas; CalGo and NT-II, which are calcium collagen complexes that support joint and bone health; CollaGo; and PetGo, a non-soluble protein. Hofseth BioCare ASA was founded in 2000 and is headquartered in Ålesund, Norway.
Hofseth BioCare ASA Fundamentals Summary
| HOFB.F fundamental statistics | |
|---|---|
| Market cap | US$71.93m |
| Earnings (TTM) | -US$13.78m |
| Revenue (TTM) | US$26.35m |
Is HOFB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HOFB.F income statement (TTM) | |
|---|---|
| Revenue | NOK 262.08m |
| Cost of Revenue | NOK 188.06m |
| Gross Profit | NOK 74.02m |
| Other Expenses | NOK 211.04m |
| Earnings | -NOK 137.02m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 07, 2025
| Earnings per share (EPS) | -0.33 |
| Gross Margin | 28.24% |
| Net Profit Margin | -52.28% |
| Debt/Equity Ratio | 84,946.8% |
How did HOFB.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/04 15:26 |
| End of Day Share Price | 2025/07/07 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hofseth BioCare ASA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jonas Peciulis | Norne Securities AS |